Table 3: Therapeutic regimens of study population.
|
Combination Antiviral |
Dosage |
||||
|
1 tablet per day |
1 tablet x 2 per week |
1 tablet x 3 per week |
Total (%) N = 28 |
||
|
SOF 400/RBV 200* |
Haemodialysis |
0 |
1 |
0 |
1 (3.6) |
|
SOF 400/DCV 60** |
Not on dialysis |
6 |
0 |
0 |
6 (21.6) |
|
SOF/VEL (400/100)*** |
Haemodialysis |
1 |
2 |
0 |
9 (32.4) |
|
|
Not on dialysis |
5 |
1 |
0 |
|
|
SOF/LDV (400/90)*** |
Haemodialysis |
1 |
7 |
1 |
12 (43.2) |
|
|
Not on dialysis |
1 |
2 |
0 |
|
SOF: Sofosbuvir; RBV: Ribavirin; DCV: Daclatasvir; LDV: Ledipasvir; VEL: Velpatasvir *RBV was taken daily; **daily intake of both molecules;comp: tablet; ***fixed suit.